Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 14/20 | 0.61 |
| ▸ | PYGL | P06737 | 5/20 | 0.49 |
| ▸ | PYGM | P11217 | 5/20 | 0.49 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3924254 | 1.00 | RIPK1 (0.61) | RIPK1PYGLPYGMDDB1CRBN | |
| SCHEMBL15957097 | 0.90 | RIPK1 (0.51) | RIPK1PYGLPYGMDDB1CRBN | |
| SCHEMBL15540370 | 0.86 | RIPK1 (0.48) | RIPK1PYGLPYGM | |
| SCHEMBL25329800 | 0.86 | RIPK1 (0.48) | RIPK1PYGLPYGM | |
| SCHEMBL19980056 | 0.82 | RIPK1 (0.51) | RIPK1PYGLPYGMDDB1CRBN | |
| SCHEMBL1269024 | 0.82 | RIPK1 (0.52) | RIPK1PYGLPYGM | |
| SCHEMBL12376347 | 0.82 | RIPK1 (0.52) | RIPK1PYGLPYGM | |
| SCHEMBL1269028 | 0.82 | RIPK1 (0.52) | RIPK1PYGLPYGM | |
| SCHEMBL3989268 | 0.82 | PYGL (0.53) | RIPK1PYGLPYGMDDB1CRBN | |
| SCHEMBL3914513 | 0.82 | PYGL (0.53) | RIPK1PYGLPYGMDDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2956452-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2015-12-23 | — | — | EP | disclosed |
| WO-2014125444-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-08-21 | — | — | WO | disclosed |
| US-20090099152-A1 | 2-ALKOXY-3,4,5-TRIHYDROXY-ALKYLAMIDE-BENZAZEPINES, THE PREPARATION AND USE THEREOF, AND COMPOSITIONS CONTAINING THE SAME | SANOFI-AVENTIS (FR) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099152-A1 | 2-ALKOXY-3,4,5-TRIHYDROXY-ALKYLAMIDE-BENZAZEPINES, THE PREPARATION AND USE THEREOF, AND COMPOSITIONS CONTAINING THE SAME | GABRA5, GABRA2, GABRA3 | RIPK1 4813/4885PYGL 3145/4885PYGM 4492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.